Brugaletta S - Search Results

1

Emergent versus elective percutaneous stent implantation in the unprotected left main: long-term outcomes from a single-center registry.

Martin-Yuste V, Alvarez-Contreras L, Brugaletta S, Ferreira-Gonzalez I, Cola C, Garcia-Picart J, Martí V, Sabate M. Martin-Yuste V, et al. Among authors: brugaletta s. J Invasive Cardiol. 2011 Oct;23(10):392-7. J Invasive Cardiol. 2011. PMID: 21972154

2

Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective.

Brugaletta S, Burzotta F, Sabaté M. Brugaletta S, et al. Expert Opin Pharmacother. 2009 Apr;10(6):1047-58. doi: 10.1517/14656560902837998. Expert Opin Pharmacother. 2009. PMID: 19364252 Review.

3

Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.

Cola C, Brugaletta S, Martín Yuste V, Campos B, Angiolillo DJ, Sabaté M. Cola C, et al. Among authors: brugaletta s. Vasc Health Risk Manag. 2009;5(1):101-19. doi: 10.2147/vhrm.s4248. Epub 2009 Apr 8. Vasc Health Risk Manag. 2009. PMID: 19436654 Free PMC article. Review.

4

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.

Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Valgimigli M, et al. Among authors: brugaletta s. Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15. Circulation. 2009. PMID: 19528337 Clinical Trial.

5

Letter by Brugaletta et al. regarding article, "Interference of drug-eluting stents and endothelium-dependent coronary vasomotion: evidence for device-specific responses".

Brugaletta S, Yuste VM, Sabaté M. Brugaletta S, et al. Circ Cardiovasc Interv. 2009 Apr;2(2):e1; author reply e2. doi: 10.1161/CIRCINTERVENTIONS.109.852996. Circ Cardiovasc Interv. 2009. PMID: 20031697 No abstract available.

6

Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.

Ferreira-González I, Marsal JR, Ribera A, Permanyer-Miralda G, García-Del Blanco B, Martí G, Cascant P, Martín-Yuste V, Brugaletta S, Sabaté M, Alfonso F, Capote ML, De La Torre JM, Ruíz-Lera M, Sanmiguel D, Cárdenas M, Pujol B, Baz JA, Iñiguez A, Trillo R, González-Béjar O, Casanova J, Sánchez-Gila J, García-Dorado D. Ferreira-González I, et al. Among authors: brugaletta s. Circulation. 2010 Sep 7;122(10):1017-25. doi: 10.1161/CIRCULATIONAHA.110.938290. Epub 2010 Aug 23. Circulation. 2010. PMID: 20733100 Clinical Trial.

7

Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation.

Niccoli G, Conte M, Cosentino N, Todaro D, Brugaletta S, Montone RA, Minelli S, Fracassi F, Galiffa V, Leone AM, Burzotta F, Porto I, Trani C, Crea F. Niccoli G, et al. Among authors: brugaletta s. J Invasive Cardiol. 2011 Jan;23(1):16-20. J Invasive Cardiol. 2011. PMID: 21183765

8

Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry.

Martin-Yuste V, Brugaletta S, Ferreira-González I, Cola C, Alvarez-Contreras L, de Antonio M, Martí V, García-Picart J, Sabaté M. Martin-Yuste V, et al. Among authors: brugaletta s. EuroIntervention. 2011 Feb;6(7):831-7. doi: 10.4244/EIJV6I7A143. EuroIntervention. 2011. PMID: 21252017

9

Letter by Brugaletta et al regarding article, "Vascular reactivity and flow characteristics of radial artery and long saphenous vein coronary bypass grafts: a 5-year follow-up".

Brugaletta S, Martin-Yuste V, Sabaté M. Brugaletta S, et al. Circulation. 2011 Apr 19;123(15):e412; author reply e414. doi: 10.1161/CIRCULATIONAHA.110.988188. Circulation. 2011. PMID: 21502580 No abstract available.

10

Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents.

Sarno G, Räber L, Onuma Y, Garg S, Brugaletta S, van Domburg RT, Pilgrim T, Pfäffli N, Wenaweser P, Windecker S, Serruys P. Sarno G, et al. Among authors: brugaletta s. Am J Cardiol. 2011 Jul 15;108(2):195-201. doi: 10.1016/j.amjcard.2011.03.023. Epub 2011 Apr 29. Am J Cardiol. 2011. PMID: 21529741

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

398 results

Search Page

Filters